Literature DB >> 31724824

PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.

Sharri Cyrus1, Deepika Burkardt2, David D Weaver3, William T Gibson1,4.   

Abstract

The EZH2, EED, and SUZ12 genes encode proteins that comprise core components of the polycomb repressive complex 2 (PRC2), an epigenetic "writer" with H3K27 methyltransferase activity, catalyzing the addition of up to three methyl groups on histone 3 at lysine residue 27 (H3K27). Partial loss-of-function variants in genes encoding the EZH2 and EED subunits of the complex lead to overgrowth, macrocephaly, advanced bone age, variable intellectual disability, and distinctive facial features. EZH2-associated overgrowth, caused by constitutional heterozygous mutations within Enhancer of Zeste homologue 2 (EZH2), has a phenotypic spectrum ranging from tall stature without obvious intellectual disability or dysmorphic features to classical Weaver syndrome (OMIM #277590). EED-associated overgrowth (Cohen-Gibson syndrome; OMIM #617561) is caused by germline heterozygous mutations in Embryonic Ectoderm Development (EED), and manifests overgrowth and intellectual disability (OGID), along with other features similar to Weaver syndrome. Most recently, rare coding variants in SUZ12 have also been described that present with clinical characteristics similar to the previous two syndromes. Here we review the PRC2 complex and clinical syndromes of OGID associated with core components EZH2, EED, and SUZ12.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Cohen-Gibson syndrome; SUZ12-related overgrowth; Weaver syndrome; overgrowth; polycomb repressive complex 2

Mesh:

Substances:

Year:  2019        PMID: 31724824     DOI: 10.1002/ajmg.c.31754

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  16 in total

Review 1.  PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function.

Authors:  Xiuli Liu; Xin Liu
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

2.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

Review 3.  The control of polycomb repressive complexes by long noncoding RNAs.

Authors:  Jackson B Trotman; Keean C A Braceros; Rachel E Cherney; McKenzie M Murvin; J Mauro Calabrese
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-04-16       Impact factor: 9.957

4.  Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity.

Authors:  Sara A Miller; Manashree Damle; Jongmin Kim; Robert E Kingston
Journal:  Development       Date:  2021-04-15       Impact factor: 6.868

Review 5.  Chromatin Remodeling in the Brain-a NuRDevelopmental Odyssey.

Authors:  Sarah Larrigan; Sujay Shah; Alex Fernandes; Pierre Mattar
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

6.  A conserved BAH module within mammalian BAHD1 connects H3K27me3 to Polycomb gene silencing.

Authors:  Huitao Fan; Yiran Guo; Yi-Hsuan Tsai; Aaron J Storey; Arum Kim; Weida Gong; Ricky D Edmondson; Samuel G Mackintosh; Haitao Li; Stephanie D Byrum; Alan J Tackett; Ling Cai; Gang Greg Wang
Journal:  Nucleic Acids Res       Date:  2021-05-07       Impact factor: 16.971

Review 7.  Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation.

Authors:  Florian Perner; Scott A Armstrong
Journal:  Cells       Date:  2020-12-21       Impact factor: 6.600

8.  The phenomenal epigenome in neurodevelopmental disorders.

Authors:  Ummi Ciptasari; Hans van Bokhoven
Journal:  Hum Mol Genet       Date:  2020-09-30       Impact factor: 6.150

9.  Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.

Authors:  Dong-Yan Zhang; Qing-Can Sun; Xue-Jing Zou; Yang Song; Wen-Wen Li; Ze-Qin Guo; Shan-Shan Liu; Li Liu; De-Hua Wu
Journal:  J Exp Clin Cancer Res       Date:  2020-10-29

10.  EZH2 is a potential prognostic predictor of glioma.

Authors:  Yi-Nan Chen; Shi-Qiang Hou; Rui Jiang; Jun-Long Sun; Chuan-Dong Cheng; Zhong-Run Qian
Journal:  J Cell Mol Med       Date:  2020-12-04       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.